Prostate Cancer Treatment Market Top Companies Analysis To reach $9,904 million Your Business by 2026
Pune, Maharashtra, India, September 22 2020 (Wiredrelease) Allied Analytics :According to the report by Allied Market Research, the global prostate cancer treatment market is estimated to register a CAGR of 4.6% from 2019 to 2026. The research helps leading players and startups to devise new strategies based on current market trends and changing dynamics. Competitive landscape is mentioned in the report based on business segments, products portfolio, and strategic moves developments of leading market players. Detailed segmentation assists in determining growing segments and determining further steps to capitalize on lucrative segments. Regional landscape is helpful in determining opportunities and driving factors of each region and taking further steps.
Prostate cancer is a type of cancer that develops into male reproductive system. Prostate cancer begins when normal cells in the prostate gland start multiplying uncontrollably. It is more prevalent in geriatric men over the age of 65 years. Risk factors for development of prostate cancer are family history, race, and old age. It can be treated by radiation therapy, surgery, chemotherapy, biological therapy, and hormone therapy. The treatment for prostate cancer can be decided on the basis of the stage of cancer. The healthcare professionals such as radiation oncologists and urologists treat prostate cancer.
To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/2653
The prostate cancer treatment market is expected to experience significant growth during the forecast period, owing to rise in prevalence of prostate cancer, increase in demand for prostate cancer treatment products, strong emerging pipeline drugs, availability of new prostate cancer treatments, and increase in awareness among people regarding the treatments of prostate cancer. In addition, surge in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) metastatic hormone nave (mHNPC) prostate cancer settings, rise in geriatric population, improved RD investment by drug innovators, rise in generic products, increase in healthcare expenditure in the developed and developing regions, growth in pharmaceutical industries diagnostic centers across the globe are expected to further drive the growth of the global prostate cancer treatment market. However, prolonged treatment durations and poor demand for prostate cancer treatment drugs in underdeveloped countries are expected to restrain the growth of the market.
Based on drug type, the prostate cancer treatment market is categorized into chemotherapy, biological therapy, and hormone therapy. Presently, hormone therapy segment dominates the global market, and is anticipated to continue this trend during the forecast period. The key factors that drive the prostate cancer treatment market growth include rise in prevalence of prostate cancer coupled with growing public awareness regarding the treatments of prostate cancer, surge in demand for hormone therapy drugs, availability of generic drugs, and increase in number of pharmaceutical companies across the globe.
Based on distribution channel, the market is classified into hospital pharmacies, drug stores retail pharmacies, and online pharmacies. Currently, the hospital pharmacies segment accounted for the majority of market share, owing to rise in number of hospitalized prostate cancer patients, convenience offered by them, and strong presence of hospital pharmacies across the globe. The online pharmacies is the fastest growing segment, at a CAGR of 6.4% from 2019 to 2026, owing to increase in preference for online purchasing of drugs over the traditional methods, increase in awareness regarding online pharmacies, and rise in number of internet users.
North America accounted for approximately one-half of the global prostate cancer treatment market share in 2018, and is expected to remain dominant throughout the forecast period. This was attributed to the higher adoption of prostate cancer treatment products, large presence of pharmaceutical companies, well developed healthcare infrastructure, and wide availability of prostate cancer treatment drugs. On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, developing RD sector, rise in healthcare reforms, and technological advancements in the field of healthcare.
Inquire Before Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2653
The Major Key Players Are:
Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson Johnson, and Takeda Pharmaceutical Company Ltd.
Key Findings of the Study:
Based on drug type, the hormone therapy segment held more than one-third share in the global prostate cancer treatment market in 2018.
Based on distribution channel, the hospital pharmacies segment held more than half share in the global market in 2018.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.6% during the forecast period.
Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of Market Research Reports and Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at email@example.com.